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Abstract
Natural selection among tumor cell clones is thought to produce hallmark properties of malignancy. Efforts to understand
evolution of one such hallmark—the angiogenic switch—has suggested that selection for angiogenesis can ‘‘run away’’ and
generate a hypertumor, a form of evolutionary suicide by extreme vascular hypo- or hyperplasia. This phenomenon is
predicted by models of tumor angiogenesis studied with the techniques of adaptive dynamics. These techniques also
predict that selection drives tumor proliferative potential towards an evolutionarily stable strategy (ESS) that is also
convergence-stable. However, adaptive dynamics are predicated on two key assumptions: (i) no more than two distinct
clones or evolutionary strategies can exist in the tumor at any given time; and (ii) mutations cause small phenotypic
changes. Here we show, using a stochastic simulation, that relaxation of these assumptions has no effect on the predictions
of adaptive dynamics in this case. In particular, selection drives proliferative potential towards, and angiogenic potential
away from, their respective ESSs. However, these simulations also show that tumor behavior is highly contingent on
mutational history, particularly for angiogenesis. Individual tumors frequently grow to lethal size before the evolutionary
endpoint is approached. In fact, most tumor dynamics are predicted to be in the evolutionarily transient regime throughout
their natural history, so that clinically, the ESS is often largely irrelevant. In addition, we show that clonal diversity as
measured by the Shannon Information Index correlates with the speed of approach to the evolutionary endpoint. This
observation dovetails with results showing that clonal diversity in Barrett’s esophagus predicts progression to malignancy.
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Introduction
Natural selection has long been recognized as the ultimate
driver of cancer progression and pathogenesis (see [1] for a recent
review; see also [2]). In early stages of tumor progression,
heterogeneous populations of malignant and healthy cells compete
for available resources. Tumor cell clones that have acquired, via
mutation and epigenetic effects, malignant ‘‘hallmark’’ phenotypes
[3,4] gain proliferative and (or) survival advantages relative to
other lineages in their tumor microenvironment. Eventually the
hallmark-carrying mutant clones come to dominate the tumor and
destroy tissue homeostasis. If this interpretation is correct, then the
mechanism causing malignancy—heritable variation conferring
advantages to particular clonal lineages—is precisely evolution by
natural selection.
Explaining the adaptive significance of most cancer hallmarks is
straightforward. However, angiogenesis—the ability of tumors to
generate their own vascular infrastructure—presents a difficult
case. Angiogenesis is coordinated directly and indirectly by cancer
cells using a variety of signaling molecules, including vascular
endothelial growth factor (VEGF), angiopoietins, fibroblastic
growth factors (FGFs), platelet-derived growth factor (PDGF),
epidermal growth factor (EGF), transforming growth factors
(TGFa and -b), and thrombospondin-1 (TSP-1), among others.
These factors act in a variety of ways on vascular endothelial cells
and (or) their precursors. Target cell responses include prolifer-
ation, chemotaxis and differentiation into functional microvessel
endothelial cells [3–6]. The balance between pro- and anti-
angiogenic molecules in the local milieu define the ‘‘angiogenic
signal’’ [7]. In hypoxic tissues, this balance tips in favor of
angiogenesis [5,6]. Cancer is often characterized by derangement
of this signaling system, generating among certain tumor clones
more-or-less constitutive production of pro-angiogenic signals and
receptors, a condition referred to as the angiogenic switch [3,4,7–
12]. The intensity of this switch varies among tumors even of the
same histological type and tissue of origin [4,13].
Angiogenesis clearly benefits tumors. In addition to nutrient
delivery and waste removal, tumor microvessels provide routes for
metastasis. However, all tumor cells receive the benefits of
angiogenesis whether or not they participate in producing the
signal. Therefore, the signal is a public good. As is well known
from decades of research into the ‘‘free-rider’’ problem in
economics and evolutionary biology, public goods are susceptible
to exploitation by free-riders. In this context, free-riders would be
clones that, by mutation or epigenetic alteration, decrease or stop
their own production of proangiogenic signals. Since metabolic
energy is required to produce the angiogenic signal, free-riders
eliminate one drain on internal energy reserves with no immediate
detriment. However, they gain an immediate advantage—saved
energy reserves can be committed to proliferation and
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maintenance metabolism. Free-rider clones would therefore be
expected to expand more rapidly than angiogenic clones due to
their inherited advantage. The obvious fact that the tumor, and
the free-riders themselves, would suffer hypoxia once free-riding
becomes dominant is irrelevant. Natural selection does not act to
benefit the tumor. Selection simply favors clones with the highest
growth and survival potential once the chains of kin selection and
other evolutionary forces compelling cooperation have been
broken. In any environment, even severely hypoxic ones, free-
rider clones will always have an advantage over angiogenic clones,
all else being equal, because they have less demand for energy to
produce a public good. Any angiogenic clone will certainly benefit
from being angiogenic. But the free-rider benefits equally. The fact
that cancer cells tend to disperse from unfavorable environments
does not eliminate the problem. It simply spreads it. If the
hallmarks of cancer are consequences of evolution, it is not
immediately clear why the angiogenic switch persists in malignant
tumors.
Indeed, modeling studies initiated by one of us (JDN) predict
that such nonangiogenic free-riders can damage or perhaps
destroy all or part of a growing tumor [14–16]. This predicted
‘‘tumor-on-a-tumor’’ phenomenon has a conceptual sister, viz.
hyperparisitism—one parasite exploiting another. Therefore, the
parallel term ‘‘hypertumor’’ was suggested to describe it [14], and
it has since been recognized as a form of evolutionary suicide
[17,18].
The early hypertumor models were limited by the fact that costs
associated with hallmark phenotypes could not be investigated
because the models lacked a proper description of energetic trade-
offs. That limitation was addressed in a recent study by Nagy and
Armbruster [17] in which the original models were extended to
include an energetic ‘‘opportunity cost.’’ This extension required
the addition of a submodel describing intracellular adenylate
dynamics to the existing tissue-level model of angiogenesis. The
result was a multiscale system with three distinct spatial and
temporal levels: intracellular energy metabolism on scales of mm
and seconds to minutes; tissue-level on scales of mm and hours to
days; and evolutionary, with scales of cm and months to years
(Fig. 1). In this formulation, ATP, the primary energy currency in
cells, is partitioned among three major energetically demanding
programs: proliferation, cell maintenance and secretion.
This model confirms that evolution of hallmarks acting on
proliferation rate differs markedly from evolution of the angiogenic
switch. In particular, selection drives energy allocation for
proliferation to an intermediate state that balances evolutionary
benefits of reproduction with opportunity costs of shunting
reducing power away from cell maintenance. This attracting state
is an evolutionarily stable strategy (ESS) sensu Maynard Smith and
Price [19,20]; that is, it is a strategy that, when used by almost all
residents of a population, cannot be invaded by any possible
mutant. This ESS is also convergence stable (essentially an
evolutionary attractor; see [21] for a review).
In contrast, angiogenic potential does not evolve to an
intermediate state in this model. As predicted by the free-rider
argument, direct selection on angiogenesis signaling is powerless to
produce the angiogenic switch via the benefits of eventual
increased perfusion. However, this model predicts an indirect
evolutionary pathway to the angiogenic switch caused by an
interesting property of the adenylate homeostasis mechanism.
Both modeling and in vivo studies suggest that intracellular
equilibrium ATP concentration is a unimodal function of overall
cell metabolic rate [11,23]. To the left of the mode (relatively low
metabolic rates), cells respond to slight increases in ATP
consumption by excessively ramping up de novo adenylate synthesis,
resulting in a paradoxical increase in equilibrium ATP concen-
tration. Therefore, under conditions favoring such overcompen-
sation, mutants that increase production of the angiogenic signal,
which requires ATP for protein synthesis and secretion, can gain
more ATP for proliferation. This pleiotropic effect on both
proliferation and angiogenic potential confers to the mutant a
selective advantage. In the model, the evolutionary picture is
complicated by an interaction between this phenomenon and the
neovascularization in response to the angiogenic signal. This
interaction generates an ESS that is always evolutionarily repelling
(details in [17]). That is, if clones differ only in ATP allocation to
angiogenesis, clones slightly more (or less) committed to angio-
genesis than the ESS are vulnerable to invasion by a mutant clone
with higher (respectively, lower) energy allocation to angiogenesis.
Therefore, this model predicts that, given enough time, selection
will run away either to vascular hyper- or hypoplasia, eventually
reaching a tumor inviability region. The latter possibility is the
original hypertumor prediction, while the former represents a
novel form of evolutionary suicide [14,16,17].
The open questions we address here are the following: (i) what
are the likely trajectories tumors traverse through their evolution-
ary ‘‘strategy spaces’’ as angiogenic and proliferative potentials
evolve? (ii) what variation in these evolutionary trajectories can be
expected? and (iii) how rapidly will the traverse occur? Answers to
these questions are required before practically testable predictions
from the model can be distilled, but they could not be addressed in
the previous modeling attempts. In these studies, the evolutionary
analysis relied on the techniques of adaptive dynamics [21,24,25],
which require the assumption that mutation dynamics are much
slower than ecological dynamics. At most only two competing
clones can exist in a tumor. One arises as a rare mutant within a
tumor populated almost exclusively by a resident clone. Compet-
itive exclusion is the rule in these pairwise bouts; either the mutant
invades the tumor and eliminates the resident clone, or the
resident eliminates the mutant. Either way, ‘‘ecological’’ dynamics
of competition are assumed to reach their endpoint before a new
mutant arises, so ecological and evolutionary timescales decouple.
Also, all mutations are assumed to have a small effect; therefore,
the difference between phenotypes of resident and mutant clones is
always small [25]. Given the genomic instability characteristic of
many malignant tumors [4], these assumptions are likely to be
violated in real tumors. So, here we repeat the evolutionary
analysis with the adaptive dynamics assumptions relaxed. To
achieve this, we first define a stochastic simulation analogue of the
multiscale evolutionary model in [17]. The equations governing
intracellular adenylate, tumor growth and angiogenesis are
unchanged. The only alteration we introduce is at the evolutionary
scale. In particular, we allow an indefinite number of clones to
compete at the same time, and mutant clones arise at random
times independent of the current state of the system. Here we show
that relaxation of the adaptive dynamics assumptions has no effect
on predicted evolutionary endpoints from the original adaptive
dynamics analysis. However, the simulations predict that evolu-
tionary dynamics of both angiogenesis and proliferative capacity is
dominated by mutational history. Practically, this prediction
suggests that the disease is on an evolutionary transient throughout
its clinical course—that is, an attracting ESS is rarely if ever
approached—and the tumor’s evolutionary tempo and trajectory
are largely determined by phenotypes of early mutants, which in
practice are likely to resist prediction. We refer to this prediction as
the historical contingency effect, following [26].
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Methods
The deterministic model underlying our simulations [17]
comprise two distinct systems of ordinary differential equations
(ODEs) governing dynamics at three time and spatial scales (Fig. 1).
The first system, which extends the pioneering work of Martinov,
Ataullakhanov, Vitvitsky and colleagues [22,23], tracks intracel-
lular adenylate dynamics, with adenylate concentrations scaled in
fmol and time scaled in mins (‘‘Energetics Scale’’ in Fig. 1). The
second system, operating at tissue and evolutionary scales,
describes growth dynamics of the tumor, dynamics of its vascular
infrastructure and competition among clones within the tumor.
The tumor is assumed to comprise some number of genetically
and phenotypically distinct clones, a collection of immature
vascular endothelial cell precursors (VECPs) and patent, functional
microvessels. In the original formulation, the number of compet-
ing clones was limited to 2, but here we allow the tumor to house
an arbitrary number, S, of distinct clones. Dynamics of a single
clone (‘‘Tissue Scale’’ in Fig. 1) is governed by two ODEs—one for
clonal mass (in g) and one for mean tumor microvessel density.
Time is scaled in days. Overall tumor dynamics (‘‘Evolutionary
Scale’’ in Fig. 1) is therefore determined by Sz2 ODEs, one for
each clone, plus equations for VECPs and microvessels, with
dependencies on the energetic states of cells determined by
equations at the energetics scale. This tissue-level model is derived
directly from previous work of Nagy and colleagues [14,16].
Interactions among all three scales revolve around tumor
perfusion, measured as microvessel length density. In the model,
Figure 1. Schematic representation of the multiscale model. The ‘‘energetic scale’’ submodel [equations (1) through (10)] governs dynamics
of adenylate (AMP, ADP and ATP). Interconversions among the three species occur via maintenance metabolism (e.g., biosynthesis, volume control),
chemical energy to support proliferation and angiogenesis signal production, glycolysis and, most importantly, the adenylate kinase reaction, among
others. Sources for adenylate include de novo synthesis of AMP and salvage from nucleic acid catabolism. Adenylate sinks include AMP destruction by
deaminases and nucleotidases and ATP loss to nucleic acid synthesis. Clonal expansion or regression at the tissue scale [model (11)] depends
primarily on mean tumor microvessel density, which is controlled in part by angiogenic factor secretion by existing clones. Blood vessels grow from
existing vasculature via chemotaxis and maturation of vascular endothelial cell precursors in and near the tumor. At the evolutionary scale,
angiogenic and proliferative potential varies among clones (different colored cell subpopulations) as they compete for resources delivered by
microvessels. Evolutionary scale dynamics are handled in the simulation (see ‘‘Simulation Methods’’ above).
doi:10.1371/journal.pone.0091992.g001
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hypoxic tumor cells secrete a chemical signal composed of a
variety of tumor angiogenesis factors (TAF) to which VECPs
respond by proliferating, maturing and integrating themselves into
functional microvessels. The interaction between intracellular and
tissue levels arises as cells partition their available chemical
potential energy, primarily in the form of ATP, among three
energy-dependent activities: maintenance metabolism (cell volume
regulation, maintenance protein production and other life-support
physiology), proliferation and, potentially, secretion of TAF. In
turn, these three activities feed into tissue-level phenomena of
blood vessel growth and clone-specific expansion. These growth
phenomena then feed back to the intracellular scale because
relative growth rates of vessels and tumors determine perfusion
and therefore nutrient delivery, which in turn sets the cellular
energy charge and ATP regeneration rate, as detailed below.
Tumor vascular dynamics depend on both the strength of the
angiogenic signal and rate of tumor growth. Tumor vascular
density determines rate of ATP synthesis. Since malignant tumors
are often characterized by dampened oxidative metabolism
(Warburg effect [27,28]), vascular feedback on ATP synthesis
primarily occurs via delivery of glucose for glycolysis (Fig. 1).
Although an exhaustive derivation of the model can be found in
[17] (see also [14]), we provide a detailed outline below for
completeness. All parameters in the model have been estimated
carefully from data when possible or from biological first principles
and model behavior when not. Details of the prarameterizations
are outside the scope of this paper but are available in references
[14,16,17].
Cell Energetics Scale Model
Let A1i(t), A2i(t) and A3i(t) represent mean intracellular
concentrations of adenylate 59 mono-, di- and triphosphate,
respectively, in clonal lineage i[f1,2, . . . ,Sg at time t[½0,?).
(Variables and parameters in this model are summarized in
Tables 1 and 2, respectively.) We assume that each clone acts
independently of all others, and all cells in a given lineage are
identical. Adenylate concentrations are to be understood as mean-
field or ensemble averages within clone i.
Intracellular adenylate dynamics are governed by the following
system of ODEs:
dA1i
dt
~aazk(A
2
2i{A1iA3i)zaiA3i{f (A1i,A3i),
dA2i
dt
~2k(A1iA3i{A
2
2i)zbA3i{G(wi,v)A2i,
dA3i
dt
~G(wi,v)A2i{ciA3izk(A
2
2i{A1iA3i),
i [f1,2, . . . ,Sg:
8>>>><
>>>>:
ð1Þ
Total adenylate in cells is controlled primarily via synthesis and
destruction of AMP. In the model, AMP appears de novo at
constant rate aaw0, representing mainly synthesis from inosine
monophosphate and salvage from nucleic acid recycling. The
function f (A1i,A3i) represents irreversible AMP recycling by
enzymes primarily in the 5
0
nucleotidase and AMP deaminase
families. Specifically,
f (A1i,A3i) :~M1
A1i
k1zA1i
 4
z
M2A1i(k2zA3i)
k3zk4A1izA
2
1i
, ð2Þ
which is an empirical model of AMP destruction suggested by
Martinov et al. [23], who also provided empirical estimates of
(positive) parameters M1, M2, k1, k2 and k3. The first and second
terms in equation (2) represent the actions of AMP deaminases and
5
0
nucleotideases, respectively.
In resting mammalian cells, adenylate dynamics are dominated
by the adenylate kinase reaction,
2ADP'AMPzATP, ð3Þ
which is represented in the model by the second, first and third
terms in each equation of model (1), respectively. In most cells this
reaction has approximately equal forward and backward rates
[29], which we denote here as the positive constant k.
Besides the adenylate kinase reaction (3), interconversion among
adenylate species revolves around either ATP hydrolysis or
synthesis. The former is primarily governed by positive parameters
ai, b and ci, which themselves are sums of constants representing
metabolism supporting proliferation, TAF secretion and mainte-
nance. In particular,
ai~b1zcazgizfi(v), ð4Þ
b~b2zca, ð5Þ
ci~aizbzm{ca, ð6Þ
for i[f1,2, . . . ,Sg. Parameters b1,b2w0 are basic maintenance
metabolism rates. The former is the ATPRAMP conversion rate,
e.g., for biosynthesis (amino acid adenylation) and to power the
phosphoribosyl pyrophosphate synthetase reaction, among others
[17]. The latter (b2) represents the ATPRADP conversion rate,
primarily, but not exclusively, for cell volume control. A second
pathway from ATP to both ADP and AMP exists via the
adenosine kinase reaction,
ATPzAdenosine?ADPzAMP,
which we assume occurs at base rate caw0. Parameter mw0 is the
per-ATP rate of nucleic acid synthesis (assumed to be an
irreversible sink for ATP). All these parameters are assumed
constant across clones.
The key evolutionary parameters are gi and f^i, both positive
constants representing mean per-molecule rates at which clone i
cells allocate ATP to proliferation and angiogenesis secretion,
respectively. The dependence of fi on v arises because clones vary
the intensity of their angiogenic signal as a function of vascular
density. Specifically, we assume that
Table 1. Dependent variables studied in this model.
Variable Meaning
t Time
Aj(t) Concentration of adenylate 59 j-phosphate
xi(t) Mass of the i
th clone’s parenchymal cells
x(t) Total parenchymal mass
y(t) Total mass of precursor VECs
z(t) Total length of mature microvessels
v(t) Tumor vascularization ( = z/x)
doi:10.1371/journal.pone.0091992.t001
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fi(v)~f^ive
{jv, i[f1,2, . . . ,Sg, ð7Þ
where v is vascular density (defined in the Tissue Scale section
below). This functional form, adapted from [14], assumes that
TAF signaling rate is a unimodal function of vascular density, v. It
qualitatively mirrors observed increases in secretion of angiogen-
esis-promoting growth factors as cells become hypoxic [5] with the
added assumption that cells suffering extreme hypoxia lose the
ability to produce the signal. Parameter jw0 is constant across
clones and determines the vascular density at which angiogenesis
secretion peaks. Parameter f^i§0 varies among clones, is constant
within a clone, and measures the general intensity of the
angiogenic signal.
Finally, ATP is ‘‘regenerated’’ from ADP primarily via
glycolysis in cancer cells. This conversion is governed in the
model by the function G(w,v). Here, w denotes the ‘‘energy
charge’’ of a cell, which is a sort of weighted average of ‘‘high
energy’’ phosphoryl groups in adenylate. Specifically,
wi :~
A3iz(1=2)A2i
A1izA2izA3i
ð8Þ
is the mean energy charge of cells in the ith clone. Mean glycolysis
rate is assumed to vary among clones only as they vary in mean
energy charge; in particular,
G(wi,v) :~4s(v)wi(1{wi), ð9Þ
where
s(v) :~
smaxv
0:1zv
, ð10Þ
and smaxw0 is constant. The particular forms and parameteriza-
tions for G(w,v) [equation (9)] and s(v) [equation (10)] were chosen
to fit data from [22] (see [17] for details).
Tumor Tissue Scale Model
Let xi(t), i[f1,2, . . . ,Sg, be the mass (in g) of clone i at time
t[½0,?). Also let y(t) and z(t) be VECP mass (in g) and total
length of microvessels, respectively, within the tumor at time t.
Microvessel length is scaled such that z~1 when total length of
microvessels in the tumor equals that of 1 g of healthy tissue in the
tumor’s site of origin [14,17]. We assume that mean proliferation
and angiogenesis signal production for cells of clone i depend on
Table 2. Parameters and default values representing a resting cell (from [17]).
Parameter Meaning Default Units
Evolutionary
l Mutation rate parameter 0.1 hr21
gi Proliferation secretion effort of clone i 1, max = 12 min
21
f^i Basic TAF secretion effort of clone i 0.11 g/U/min
Energetic
aa de novo AMP synthesis rate 5.725610
25 fmol/min
k Adenylate kinase rate parameter 106 1/fmol/min
b1 Maintenance ATP to AMP rate 4 min
21
b2 Maintenance ATP to ADP rate 4 min
21
ca Adenosine kinase rate 0.01 min
21
m ATP destruction rate 0.01 min21
j Nutrient sensitivity of TAF secretion 10/3 g/U
smax Physiological max ATP regeneration rate 390 min
21
M1 AMP deaminase parameter 0.4 fmol/min
M2 Nucleotidase parameter 9.167610
27 fmol/min
k1 AMP deaminase parameter 0.5 fmol
k2 Nucleotidase parameter 5610
23 fmol
k3 Nucleotidase parameter 2.5610
210 fmol2
k4 Nucleotidase parameter 5610
25 fmol
Tissue
p Basic parenchyma proliferation rate 0.072 hr21
ks Proliferation sensitivity parameter 2 fmol/min
m Parenchyma mortality parameter 0.0698 fmol/hr
a Max VEC response to TAF 0.1 hr21
kv Sensitivity of VECs to TAF 0.0115 fmol/min
b VEC death/maturation rate 0.04 hr21
c VEC maturation rate 3 U/g/hr
d Microvessel remoldeling rate 461023 g/U/hr
doi:10.1371/journal.pone.0091992.t002
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the clone’s mean intracellular ATP concentration. However, mean
ATP concentration depends on vascular density, v, the clone’s
energy commitment to proliferation, gi and its commitment to
angiogenesis, fi(t) (see previous section). Therefore, there is a
continuous feedback between energetic and tissue scale dynamics.
Since adenylate dynamics of model (1) equilibrate very rapidly on
the time scale of the tissue model (11) (ref. [17]), we further assume
that mean ATP concentration in all clones is locked in quasi-
equilibrium for the adenylate model. We denote the ATP quasi-
equilibrium for the ith clone as A3i.
These assumptions lead to our tissue-level model of tumor
growth, adapted from [14,17]:
dxi
dt
~
pgi A3i
kszgi A3i
{
m
A3i
 
xi, i[f1,2, . . . ,Sg,
dy
dt
~
PS
i~1
yi (v,
A3i )xi
x
{b,
0
BB@
1
CCAy,
dz
dt
~cy{dvz,
yi(v,
A3i) ~
afi(v)A3i
kvzfi(v)A3i
, i[f1,2, . . . ,Sg,
v ~
z
x
, x~
XS
i~1
xi:
8>>>>>>>>>>>><
>>>>>>>>>>>>:
ð11Þ
(Note that we have suppressed the time arguments of dependent
variables for clarity.) Here, v(t) denotes tumor microvessel length
density (in microvessel units/g), and z is scaled such that v~1
when tumor vascular density equals that of surrounding healthy
tissue. The mean ATP hydrolysis rate in support of proliferation in
clone i is gi A3i. Mean per-cell proliferation rate is a monotonically
increasing, saturating function of gi A3i, which we represent with a
Michaelis-Menten form in which pw0 and ksw0 are maximum
proliferation rates and half-saturation constants, respectively. We
also assume that a clone’s mean per capita mortality rate is
inversely proportional to A3i, with constant mw0.
Mean energetic commitment to angiogenic signal production in
clone i takes a similar form to that for proliferation, viz. fi(v)A3i.
As with proliferation, ATP invested in angiogenesis gives
diminishing returns, as represented by another Michaelis-Menten
function, with maximum angiogenic signal production a and half-
saturation constant kv [see equation for yi(v,
A3i) in system (11)].
Overall angiogenic signal is the average signal strength of all clones
weighted by clone density, and we assume that per capita
proliferation of VECPs is proportional to the strength of this
signal [first term, second equation in system (11)]. Mean per capita
VECP mortality and maturation rates, combined into parameter
bw0, are assumed to be fixed. As VECP cells mature, they
integrate themselves into functional tumor microvessels at rate c,
composed of both the rate constant and a unit conversion factor.
There is evidence that tumors actively maintain their vascular
infrastructure even after its initial construction [5,6,12,30].
Viewing this maintenance as the tumor provisioning microvessels
with a resource, which may simply be space, we assume that this
resource is proportional to tumor mass, say R~c1x, where c1w0
is constant. Resource availability per microvessel unit is therefore
the ratio R=z~c1x=z~c1=v. We assume that per capita
microvessel remodeling rate is inversely proportional to this ratio;
that is, it is proportional to v with proportionality constant d
(which includes c1; second term, z equation of system (11); see also
ref. [14]).
This modeling approach implicitly assumes that the average
conditions in the tumor are predictive of tumor dynamics. In
particular, vascularization, v(t), is interpreted as mean vessel
density throughout the tumor at any given time (or, alternatively,
the ensemble average of many similar tumors). However, since
mutant clones are initially localized and vary in angiogenic
efficacy, one should question the assumption that all clones are
equally vascularized on average. On the other hand, cancer cells
are characterized by their ability to infiltrate surrounding tissues,
and many if not most exhibit positive chemotaxis up nutrient
gradients and therefore tend to move towards areas of locally high
vascularization [31]. So how violated the averaging assumption is,
and the consequences of that level of violation, remain open
questions to be addressed in subsequent approximations.
Evolutionary Scale Model
The tumor’s vascular support, measured by v, reacts to changes
in the clonal composition of angiogenic phenotypes, their
prevalence and overall abundance. In turn, clonal composition is
determined by selection pressures generated by a particular
vascular environment. This interaction dictates dynamics at the
evolutionary scale. Here we follow the prevalence of each
phenotype within the tumor, where the phenotype of clone i is
defined as fgi,f^ig; that is, the phenotype is the clone’s energetic
commitment to angiogenesis and proliferation. We make no
explicit hypotheses about how these phenotypes relate to
genotypes except for the general assumptions that these traits
have high heritability, that they are polygenic, and that new
phenotypes may arise by mutation. However, we allow the
possibility that multiple genotypes can generate the same
phenotype. We also leave open the possibility that phenotype
could result from a persistent epigenetic change. For simplicity,
however, we refer to new phenotypes as ‘‘mutants.’’ In any case,
phenotype is fixed for all cells in the clone, although angiogenesis
signaling and proliferation rates in a single clone are not fixed
since these depend on vascularization, which is dynamic.
Evolutionary dynamics of clonal phenotypes in this model were
initially analyzed using adaptive dynamics [17]. The technique is
founded on the question, can a rare mutant strategy invade an
otherwise monomorphic population using a different strategy (the
‘‘resident’’ strategy) in the resident’s equilibrium environment
[21,24,25]? The set of all possible strategies is referred to as the
strategy space. One analyzes the ability of any possible mutant
phenotype to invade any resident strategy in an environment set
by the resident. Such an analysis produces a good, if not complete,
picture of the evolutionary dynamics, including the existence and
location in strategy space of evolutionarily important points or sets.
In particular, adaptive dynamics identifies evolutionarily stable
strategies (ESS), can be used to determine whether these points are
evolutionarily attracting (continuously stable strategies [32]) or
repelling and assess potential for evolutionary suicide [18] and
evolutionary branching [21], among other things.
However, adaptive dynamics is limited by two fundamental
assumptions. First, interarrival times between mutations must be
long compared to population dynamics so that fate of the mutant
is determined before the next mutant arises. Although this
assumption improves analytical tractability, it removes mutational
dynamics from the evolutionary picture, rendering transient
evolutionary dynamics invisible. We can only see the potential
evolutionary endpoints. Also, this assumption is almost certainly
violated in most cancers, which are well-known to be genomically
and genetically heterogeneous [1,33]. Second, most adaptive
Angiogenesis Evolution in Clonally Diverse Tumors
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dynamics analyses rely on the assumption that mutations have
small phenotypic effects. Although this assumption is not strictly
required, relaxing it typically compounds analytical complexity.
But again, in cancer this assumption has dubious validity because
even minor mutations in both coding and control regions of genes
can have massive effects on cell phenotype. A relevant example
here would include a mutation in the control region of HIF1A, the
gene for the a subunit of hypoxia-inducible factor 1, which could
generate an enormous alteration of a clone’s angiogenic potential
[34]. The main goal of this paper is to assess the effects these
assumptions have on the predictions of the coupled models (1) and
(11). Therefore, we relax these assumptions, at the cost of
sacrificing analytical tractability, which leads to the simulations
described below.
Simulation Methods
In concept, our simulations operate as follows. Initial tumors are
assumed to be small (10 mg) and monomorphic with vascular
density equal to that of surrounding healthy tissue (z(0)~1).
Therefore, simulation initial conditions were always the following:
x1(0)~0:01 g, xi(0)~0 for all i[f2,3, . . . ,Sg, y(0)~0:001 g,
z(0)~0:01, Aj1(0)~Aj1, j[f1,2,3g, where Aj1 are the equilibrium
concentrations in a tissue with v~1, and all Aji for j[f1,2,3g and
i[f2,3, . . . ,Sg are left undefined until they arise via mutation.
Mutations occur as discrete events, with one new mutant clone
introduced at each event. Biologically, all mutation events except
the first are assumed to be independent of time, the composition of
the tumor and the number of previous mutation events.
Mathematically we therefore assume that, if fTngS{1n~0 is the set
of arrival times for the S mutations defining new clones (assuming
that T0~0), then T1, T2{T1, . . . ,TS{1{TS{2 are independent,
identically distributed exponential random variables with param-
eter l (mean l{1; biologically, the mean interarrival times of
mutations).
On the time intervals ½Tn{1,Tn),n[f1,2, . . . ,S{1g, tumors
grow according to models (1) and (11) with xi~0 and Aji ignored
for all i[fnz1, . . . ,Sg and j[f1,2,3g. Mutant clones enter the
model when they have grown to a size large enough to be buffered
from stochastic extinction; therefore, a mutation event represents
the arrival of an already sizable mutant clone, which is assumed to
have initial mass of 0.1 mg and initial adenylate concentrations
equal to the quasi-equilibrium for that clone at the current
vascular density. So, at arrival times Tn, n[f0,1, . . . ,S{1g, the
mass of the new mutant clone, xiz1(Tn), is set instantly to 0.1 mg,
and the three adenlylate species for the new clone instantly take on
their quasi-equilibrium values for that clone given v(Tn); that is,
Aj(nz1)(Tn)~Aj(nz1)(v(Tn)),j[f1,2,3g. In the terminal time peri-
od, ½TS{1,?), the tumor grows according to models (1) and (11),
with all variables strictly positive. In practice, simulations ended at
t~4 ‘‘years.’’ This horizon ensures that tumors, if viable, will grow
beyond the model’s design, given that the model is meant to
represent tumors still growing in their exponential phase. In
addition, it allows vascular density to equilibrate so that the
evolutionarily dominant clone can more easily be defined (see
below).
In any given simulation, only one parameter, either g or f^, was
allowed to evolve—all others were fixed at their default values.
Values of g for each clone were drawn from the interval ½1,12 and
for f^ from the interval ½0,4, which includes essentially all
biologically feasible values for these parameters [17]. The
probability distributions for the draws were uniform over those
intervals because, as mentioned earlier, single mutations may have
large phenotypic effects, and a comprehensive mapping between
pathological genetic and epigenetic alterations and phenotypic
effects is unavailable. Given this uncertainty, a uniform probability
distribution is the proper prior assumption. Further uncertainty
arises in the mutation rate parameter, l. We explore the
consequences of this uncertainty by fixing l in each simulation,
but varying it between 10 and 50 hours among simulations. In
each case, however, the number of (eventually) competing clones,
S, was fixed at 50. Each simulation scenario was then repeated
1000 times with the same initial conditions.
We evaluated the evolutionary outcome of the simulation using
two measures. The first represents what would appear be the
evolutionary ‘‘winner’’ in a histopathology study. In this case, we
defined the ‘‘evolutionarily dominant,’’ or just dominant, clone to
be the clone with the largest mass at the end of the simulation (4
years). The second measure of evolutionary success conforms more
closely to an evolutionary biologist’s notion of evolutionary
advantage. In this case, we define the dominant clone as that
which has the highest per capita growth rate at simulation’s end.
These two methods frequently identified different evolutionarily
favored clones. For instance, many simulated tumors had small,
but very rapidly growing, clones within them at the end of the
simulation. These clones were clearly outcompeting all others, but
because they arose late the the natural history of the tumor, they
had not had time to impact the tumor’s histology. This
phenomenon lead us to fix S~50 mutants—mutants that arise
beyond the 50th almost always remain pathologically irrelevant.
A measure of clonal diversity within a tumor provides a concise
description of a tumor’s evolutionary state with, potentially,
clinically relevant predictive power [1,35,36]. We therefore
measure phenotypic diversity with the Shannon Diversity Index,
or Shannon Information measure [37], which quantifies the mean
relative abundance of tumor clones. Maley et al. [35] used it to
measure clonal diversity in Barrett’s esophagus, and we adopt it
here for the same reason they did—it does not overemphasize the
most common clone. Given that selection acts on clones of all
sizes, and that rate of evolution depends on availability of adaptive
phenotypes [38], Shannon’s diversity index is a better measure of
evolutionary potential than are many other commonly used
indexes, like Simpson’s. In the model, the practical difficulties of
estimation from field data [39] are eliminated. The index, H , is
defined as
H :~{
XS
i~1
qi ln qi,
XS
i~1
qi~1, ð12Þ
where qi is the proportion of the tumor mass contributed by the ith
clone. The Shannon index thus varies between 0 (a monomorphic
tumor) and lnS (all S clones contribute equally to tumor mass). If
the evolutionary endpoint is a monomorphic tumor, the Shannon
index may be used as a rough measure of how close the tumor is to
its climax histology (in the sense of the ecologist’s ‘‘climax
ecosystem’’).
Results and Discussion
Evolution of Proliferation
Our simulations show that relaxation of restrictive adaptive
dynamics assumptions do not alter the predictions of the adaptive
dynamics analysis. No matter which definition one uses for
‘‘evolutionary dominance,’’ either the histopathologist’s (most
mass) or the evolutionary biologist’s (largest per-capita growth
rate), the mean dominant g from our simulations agrees very well
with the CSS (evolutionary attracting strategy) predicted by
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adaptive dynamics; for example, with default parameter values,
the predicted ESS for proliferation effort was g&3:67 min21
(approximately 5:5 fmol or 7|109 ATP molecules per minute in a
resting cell, about half the rate measured in mouse LS cell culture
[40]) which agrees very well with our simulations (Fig. 2).
Nevertheless, the evolutionarily dominant clone at the close of
any given simulation varies, sometimes significantly, from the
theoretical ESS from adaptive dynamics. These deviations appear
to be caused by mutational contingency—although the ESS is a
deterministic evolutionary endpoint, by chance, the mutational
history [26] fails to direct the system towards the optimal g before
the tumor grows out of bounds. This picture predicts that tumors
of the same type, even in the same genetic background, will vary in
evolutionary strategy in a symmetric distribution around the ESS
(Fig. 2). However, at the whole-tumor level, the weighted mean
proliferation effort, defined as
g :~
XS
i~1
xigi
x
, ð13Þ
also tends towards the predicted ESS, as does the ensemble
average of many simulations (Fig. 3).
Historical contingency has a greater impact on the histopath-
ological picture of tumor natural history than it does on the
evolutionary view. If mutant clones nearest the ESS arise late, they
will tend to contribute little to the tumor mass as it approaches
lethality; the clone favored by selection has no time to become
histologically significant. However, these favored clones’ per capita
expansion rates are large. Therefore, the variance in ‘‘dominant
phenotype’’ will tend to be greater in the histopathological rather
than the evolutionary view (Fig. 2). This effect is magnified as
mutation rate decreases—longer mutation interarrival times gives
early-arising, suboptimal clones more time to gain bulk before
more well-adapted mutants crop up. As a result, if the number of
mutations is fixed, tumors with lower mutation rates have greater
variance in ‘‘dominant phenotype’’ at the histological level (Fig. 2,
blue plots) and take longer to approach the ESS at the whole
tumor level (Fig. 3). In contrast, since time of arrival has little effect
on per capita growth rate, mutation rate has little to no effect on
the ‘‘dominant’’ clone as defined by per capita growth rate (Fig. 2,
black plots).
These results suggest that, in clinical applications, simple
measures of clonal diversity that fail to take clonal abundance
into account, like mean phenotype or the ecologist’s ‘‘species
diversity’’ measure [39], will be inferior to metrics like the
Shannon diversity index, which magnifies the relative contribution
of rare clones to overall tumor diversity. We explore the
consequences of this suggestion by evaluating the dynamics of
diversity in our simulations, taking proliferation commitment, g, as
the phenotype (Fig. 4). In most simulations, transient dynamics in
H are longer than are transients in mean g (compare Figs. 3 and
4). Interestingly, the Shannon index tends to increase with
increasing mutation rate even though the total number of
mutations remains the same (Fig. 4). Historical contingency is
the culprit here, too. When interarrival times are relatively long,
new mutant clones have a diminishing impact on this diversity
measure since previously successful clones have more time to gain
mass before they are challenged by new mutants. In addition, H
exhibits a large variance both among tumors in the ensemble and
within a given tumor over time well after mutations have stopped
(Fig. 4, purple curves).
How this variation relates to clinical prognosis is an interesting
open question. Maley et al. [35] addressed a similar issue in
Barrett’s esophagus. Their study suggested that higher Shannon
diversity index in cell ploidy predicts progression from the
premalignant state to adenocarcinoma. These authors suggest
that this correlation is causative since higher genetic diversity
Figure 2. Evolutionarily ‘‘dominant’’ proliferation commitment (g) in 1000 simulations for each of two mutation rates: l=0.1 and
0.02 (plotted as mean interarrival time between mutations 10 and 50 hours, respectively). All parameters except g were set to the
defaults in [17]. Shown are distributions of the histopathologist’s ‘‘dominant’’ clone (clone with the most mass; blue) and the evolutionary biologist’s
dominant clone (clone with the largest per capita growth rate; black).
doi:10.1371/journal.pone.0091992.g002
Angiogenesis Evolution in Clonally Diverse Tumors
PLOS ONE | www.plosone.org 8 April 2014 | Volume 9 | Issue 4 | e91992
generally leads to more rapid evolution. In the context of the
current study, the evolutionary endpoint is the ESS. Therefore, the
same reasoning suggests that higher diversity should lead to more
rapid convergence to that endpoint. Since diversity increases with
mutation rate even for a fixed number of mutations, we therefore
expect more rapidly mutating tumors to more rapidly approach
the ESS. Indeed, the simulations predict precisely this pattern
(Fig. 3). The significance of this is two-fold. Clonal diversity not
only helps predict probability of cancer progression, it can also be
used to assess the evolutionary potential of tumors that are already
malignant. Therefore, we suggest that phenotypic diversity can be
a clinically relevant measure that can complement genomic and
genetic profiles which are at times so complicated by underlying
genetic instability that they can obscure our understanding of
tumor drivers.
Evolution of the Angiogenic switch
As described in the introduction, the Nagy-Armbruster model
[17] predicts that any ESS for angiogenesis effort (f^) is an
evolutionary repeller—rare mutant strategies further from the ESS
are favored. Selection therefore pushes mean phenotype away
from the ESS, resulting in runaway selection for either vascular
hyper- or hypoplasia. This phenomenon is caused by a complex
interaction between adenylate metabolism, energy charge homeo-
stasis and vascular response to angiogenesis signaling. The
angiogenesis ESS is also highly sensitive to proliferative effort.
For example, if g~1, representing proliferative effort in a healthy,
homeostatic tissue, the ESS f^&0:0524 min21 (about 0.08 fmol or
108 ATP molecules per min per cell). However, as g changes
towards its ESS of 3.67 (assuming it does so independently of
selection on angiogenesis potential), the ESS for f^ jumps past 90
(more than 135 fmol or 1:8|1011 ATP molecules per minute per
cell), beyond what is physiologically reasonable.
Here, as in the previous section, we relax the adaptive dynamics
assumptions of one mutant challenger at a time and small
mutational effect, although we retain the assumption that selection
acts only on angiogenesis effort. Here again, simulations agree
Figure 3. Change over time in weighted mean proliferation effort, g (see equation (13)). Blue curves in both panels represent the first 20
of the 1000 simulations plotted in Fig. 2. Solid black curves are the ensemble averages of all 1000 runs, dashed black curves mark the inner 95th
percentile range for all runs, and dotted black lines represent the ESS predicted by adaptive dynamics theory (g~3:67 min21). Dashed red lines
represent mean time of the final mutation (S=l). (A) l~0:1; (B) l~0:02.
doi:10.1371/journal.pone.0091992.g003
Figure 4. Dynamics of the Shannon diversity index, H, of individual tumors evolving in proliferation commitment, g. Purple curves in
both panels represent the first 20 of the 1000 simulations plotted in Fig. 2. Solid black curves are the ensemble averages of all 1000 runs. Dashed red
lines represent mean time of the final mutation (S=l). (A) l~0:1; (B) l~0:02.
doi:10.1371/journal.pone.0091992.g004
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with the adaptive dynamics analysis. There exists an evolutionarily
repelling ESS, so angiogenic commitment evolves to one extreme
or the other, as can be seen in Fig. 5. If proliferation commitment
is low, the angiogenesis ESS is also relatively low. In consequence,
many mutants have an angiogenic commitment above the ESS.
Because the ESS is repelling, those clones with the highest
angiogenic commitment have the greatest advantage, and so f^
evolves to its highest possible value (Fig. 5, left-hand black box).
However, if proliferation commitment is high, then the angiogen-
esis ESS is beyond what is physiologically possible but is still
repelling. Therefore, mutants with the lowest angiogenic commit-
ment are most favored, and f^ evolves to extremely low values
(Fig. 5, right-hand black box).
Nevertheless, these evolutionary forces remain clinically insig-
nificant because historical contingency completely dominates the
dynamics. By the end of the simulations, when tumors are well
beyond lethal size, strategies that dominate by mass vary greatly in
angiogenic phenotype, f^ (Fig. 5, blue boxes). Therefore, even
detailed histopathology studies would reveal no evolutionary
pattern unless specific markers for angiogenesis were correlated
Figure 5. Evolutionarily dominant tumor angiogenesis factor commitment (f^) in 1000 simulations for two values of proliferative
effort (g~1:085 min21 and 3.65 min21). In both cases, l~0:1. All other parameters except f^ were set to defaults from [17]. (Compare Fig. 2.)
doi:10.1371/journal.pone.0091992.g005
Figure 6. Change over time in weighted mean angiogenesis effort, f^. Blue curves in both panels represent the first 20 of 1000 simulations
plotted in Fig. 5. Solid black curves are ensemble averages of all 1000 runs, dashed black curves are the inner 95th percentile of all runs, and dashed
red lines are mean time of the last mutation. (Compare Fig. 3.) (A) g~1:085 min21; dotted horizontal line is the ESS from adaptive dynamics
(&0:0524 min21). (B) g~3:65 min21; the ESS value of f^w90 min21 is not shown.
doi:10.1371/journal.pone.0091992.g006
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with proliferation rate. This situation arises because the selection
gradient for angiogenesis effort is extremely shallow [17].
Although extreme values of f^ are favored, selective benefits of
these extremes are tiny compared to disfavored strategies.
Therefore, tumors tend to be dominated histologically by the
initial clones that arise because the time required by any selectively
favorable clone to overcome these early clones extends well
beyond the time required for the tumor to grow to lethal size.
Nevertheless, the general evolutionary trend towards ‘‘hypertu-
mors’’ predicted by adaptive dynamics is still evident. All
simulations show a clear trajectory towards either vascular hyper-
or hypoplasia. In particular, tumors with low proliferation
commitment (g=1.085 min21) always evolve towards higher
angiogenic potential (Fig. 6A), while tumors with high proliferation
commitment (g=3.65 min21) always creep towards failing angio-
genesis (Fig. 6B).
In the former case, tumor necrosis occurs once tumor vascular
density exceeds 3.2 times normal tissue vascularization (Fig. 7,
dashed curves). The necrosis arises as selection continues to favor
the most angiogenic clones in the (hypervascular) tumor; the
energy wasted by massive angiogenic factor secretion in an
environment that promises no more proliferative advantages to
cells from more microvessel density ends up causing the tumor’s
downfall. In contrast, the latter case represents a ‘‘classical’’
hypertumor [14] as selection favors the least angiogenic clones,
eventually forcing the vascular density below that required to
sustain the cells. Specifically, tumors with proliferation commit-
ment anywhere between 0 and 4 min21 become necrotic once
tumor vascularization drops below 0.2 (20% of normal vascular
density; Fig. 7, solid curves).
As tumors progress towards their evolutionary endpoint—the
ESS in the case of proliferative potential and extreme hypo- or
hyperplasia for angiogenic ability—clonal diversity will tend to
decrease. Therefore, the diversity index provides at least a rough
measure of how close the tumor system is to its evolutionary
endpoint. However, the picture is muddied because selection
pressures on proliferation and on angiogenic capacities interact.
Weak selective pressures on proliferation allow for increasing
Figure 7. Per capita growth rate of various strategies against tumor vascularization. Gray, dashed horizontal line represents zero growth
rate. Solid lines represent clones with high proliferation commitment (g=3.65 min21), while dashed lines represent clones with low proliferation
commitment (g=1.085 min21). Black lines represent the lowest angiogenic clones (f^=0 min21), red lines; the highest angiogenic clones
(f^= 4 min21), which encompasses the possible curves of all intermediate angiogenic clones.
doi:10.1371/journal.pone.0091992.g007
Figure 8. Dynamics of the Shannon diversity index, H, of individual tumors evolving in angiogenic commitment (f^) for two
different constant proliferation commitments: (A) g~1:085 min21; (B) g~3:65 min21. Purple curves in both panels represent the first 20 of
the 1000 simulations plotted in Fig. 5. Solid black curves are the ensemble averages of all 1000 runs. Dashed red lines represent mean time of the final
mutation (S=l), with l~0:01.
doi:10.1371/journal.pone.0091992.g008
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diversity in angiogenic capacity, whereas tumors evolving rapidly
to a high proliferation commitment tend to be significantly less
diverse (Fig. 8). Indeed, a small subset of highly proliferative
tumors exhibit rapid declines in tumor diversity (Fig. 8B); no
similar behavior was observed in tumors with low proliferation
commitment (Fig. 8A).
Given the dominant role historical contingency plays in
evolution of angiogenesis capacity in these simulations, the clinical
significance of hypertumors remains an open question. Evolution-
ary suicide may be the ultimate endpoint of angiogenic tumors,
but they may also tend to kill the host before that endpoint is
approached in many, perhaps most, cases. However, the
simulations as formulated here cannot be used to assess this
suggestion since the parameterization is focused on early tumor
growing in their exponential phase.
Conclusions
Tumors exist not as homogeneous entities with universal
properties or traits, but rather as diverse collections of heteroge-
neous cell lineages competing for resources with one another and
surrounding healthy cells within the tumor stroma. Thus, viewing
tumor progression as an evolutionary process is vital to under-
standing and eventually treating tumors so that resistance does not
evolve. Previous adaptive dynamics modeling has shown that
selection acts on cells’ commitments to proliferation and TAF
secretion potential based on their costs and benefits, defined
primarily by their effects on metabolism and per capita growth
rate [17]. However, the analytical techniques used in that study,
based on adaptive dynamics, assumes certain biological constraints
not commonly observed in cancer growing in vivo, including low
phenotypic diversity and small mutational effects. Using numerical
simulations, we relax these assumptions and show that diverse,
complex tumors still adhere to the evolutionary pathways
predicted by adaptive dynamics. In particular, (i) the ultimate
evolutionary attractor for proliferative commitment is a finite ESS
that is also convergence-stable, (ii) selection on angiogenic
potential generates an ESS that becomes an evolutionary repeller,
and therefore (iii) selection on angiogenesis potential produces
vascular instability ultimately leading to evolutionary suicide
(hypertumor) by inducing either vascular hypo- or hyperplasia.
However, evolutionary trajectories in these simulations are so
highly influenced by the tumor’s specific mutational history that
the predicted evolutionary endpoints may be largely irrelevant to
tumor natural history in vivo.
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